Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Lipidomics analysis for human liver cell lines (Study ST000685)

C18 NEGATIVE ION MODE (Analysis AN001056)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
plasmenyl-PE 32:0; [M-H]-@7.11	ME191175	1.76	0.72	1.02	0.92	0.89	0.67
PG 36:0; [M-H]-@6.91	ME191121	0.71	0.46	1.98	1.50	0.77	0.49
PI 38:5; [M-H]-@5.37	ME191153	0.60	0.66	1.78	1.72	0.51	0.57
lysoPE 22:5; [M-H]-@1.58	ME191174	0.85	0.44	2.56	0.51	0.40	1.04
plasmenyl-PE 38:5; [M-H]-@6.85	ME191185	0.56	0.77	2.31	1.00	0.74	0.54
PC 38:6; [M-Ac-H]-@6.14	ME191060	0.59	0.63	2.43	0.55	0.88	0.88
plasmenyl-PE 36:4; [M-H]-@6.70	ME191181	0.43	0.62	2.38	0.85	0.99	0.72
plasmenyl-PE 38:6; [M-H]-@6.62	ME191186	0.35	0.56	2.84	0.88	0.86	0.46
plasmenyl-PE 40:6; [M-H]-@7.23	ME191189	0.36	0.55	2.81	0.80	0.87	0.56
plasmenyl-PE 36:2; [M-H]-@7.33	ME191179	0.31	0.47	2.74	0.58	0.73	1.08
plasmenyl-PE 34:2; [M-H]-@6.75	ME191178	0.34	0.74	2.80	0.49	0.74	0.81
plasmenyl-PE 38:4; [M-H]-@7.34	ME191184	0.44	0.69	2.69	0.46	0.90	0.79
PA 38:4; [M-H]-@6.00	ME191029	0.36	0.47	1.42	0.21	1.19	2.41
PS 38:4; [M-H]-@5.95	ME191165	0.37	0.68	0.95	0.09	1.01	2.90
PS 38:3; [M-H]-@6.31	ME191164	0.24	0.75	1.24	0.15	1.00	2.62
PS 40:5; [M-H]-@6.22	ME191169	0.39	0.78	1.01	0.26	1.01	2.56
PE 35:3; [M-H]-@6.26	ME191082	0.38	1.64	0.80	0.40	1.00	1.78
PC 40:2; [M-Ac-H]-@8.08	ME191062	0.56	1.02	1.20	0.62	1.02	1.58
PC 42:4; [M-Ac-H]-@7.91	ME191068	0.54	1.11	1.20	0.49	1.04	1.64
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.83	ME191016	0.56	1.14	1.04	0.65	1.16	1.50
plasmenyl-PE 32:1; [M-H]-@6.61	ME191176	0.60	1.11	1.18	0.63	1.18	1.36
FFA(20:1)	ME191002	0.54	0.99	0.97	0.72	1.05	1.75
FFA(20:2)	ME191003	0.54	1.01	1.04	0.53	1.00	1.88
PC 37:3; [M-Ac-H]-@6.93	ME191055	0.56	1.01	1.17	0.48	0.99	1.79
FFA(22:2)	ME191007	0.44	0.98	1.00	0.56	1.00	2.01
FFA(22:3)	ME191008	0.46	0.97	0.97	0.63	1.13	1.89
PE 44:4; [M-H]-@8.58	ME191111	0.18	1.25	1.13	0.66	0.88	1.86
FFA(24:1)	ME191010	0.39	1.08	1.23	0.53	0.87	1.86
FFA(24:3)	ME191012	0.36	1.11	1.02	0.60	0.81	2.03
PE 40:4; [M-H]-@7.46	ME191103	0.55	0.78	1.40	0.69	1.14	1.49
PE 37:2; [M-H]-@7.29	ME191090	0.29	0.91	1.40	0.88	1.20	1.39
PC 33:0; [M-Ac-H]-@6.86	ME191041	0.35	0.83	1.55	0.80	1.06	1.43
PE 39:4; [M-H]-@7.21	ME191100	0.36	0.89	1.51	0.76	1.16	1.37
PE 31:0; [M-H]-@5.71	ME191070	0.36	0.91	1.41	1.01	1.02	1.29
PG 40:7; [M-H]-@5.15	ME191135	0.32	0.71	1.53	0.99	1.09	1.40
PG 42:9; [M-H]-@5.00	ME191140	0.31	0.80	1.21	0.84	1.37	1.59
PG 42:8; [M-H]-@5.31	ME191139	0.29	0.61	1.61	0.69	1.10	1.73
PG 38:6; [M-H]-@4.98	ME191131	0.28	0.75	1.35	0.79	1.16	1.72
PG 42:7; [M-H]-@5.69	ME191138	0.25	0.70	1.47	0.85	1.13	1.64
lysoPE 17:0; [M-H]-@2.07	ME191172	0.53	0.61	1.08	0.92	1.10	1.79
PG 40:8; [M-H]-@4.68	ME191136	0.30	0.58	1.25	0.92	0.96	1.98
PE 42:2; [M-H]-@8.48	ME191107	0.09	0.84	1.43	0.92	0.78	1.86
PG 38:5; [M-H]-@5.33	ME191130	0.17	0.75	1.37	0.92	0.95	1.82
FFA(22:1)	ME191006	0.42	0.90	1.32	0.76	0.94	1.64
FFA(24:2)	ME191011	0.39	0.89	1.29	0.71	0.84	1.82
PE 38:3; [M-H]-@7.31	ME191095	0.53	0.69	1.31	0.60	0.95	1.89
PE 40:3; [M-H]-@7.67	ME191102	0.35	0.76	1.38	0.55	1.07	1.91
PG 36:1; [M-H]-@6.47	ME191122	0.35	0.77	1.49	0.45	1.22	1.80
PG 36:4; [M-H]-@5.09	ME191125	0.27	0.85	1.20	0.60	0.82	2.21
plasmenyl-PE 38:1; [M-H]-@8.29	ME191182	0.29	1.00	1.15	0.43	0.81	2.26
CL 66:4; [M-2H](2-)@8.94	ME190980	0.26	0.78	1.49	0.66	0.73	1.99
PG 38:7; [M-H]-@4.47	ME191132	0.19	1.01	1.34	0.74	0.55	2.03
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.46	ME191013	0.38	1.30	1.03	0.27	1.05	1.98
CL 64:1; [M-2H](2-)@5.80	ME190977	0.11	1.20	1.38	0.40	0.98	1.91
PE 33:2; [M-H]-@6.08	ME191076	0.18	1.06	1.48	0.28	1.13	1.92
PE 34:3; [M-H]-@5.99	ME191077	0.25	1.07	1.47	0.22	1.09	1.93
PE 34:4; [M-H]-@5.71	ME191078	0.30	1.21	1.25	0.28	1.15	1.87
PE 31:1; [M-H]-@6.06	ME191071	0.20	1.13	1.26	0.31	1.19	1.96
PE 44:5; [M-H]-@8.11	ME191112	0.19	1.09	1.30	0.36	1.12	1.98
PI 34:1; [M-H]-@5.69	ME191144	0.46	0.89	1.19	0.23	1.05	2.20
PS 34:1; [M-H]-@5.82	ME191158	0.25	1.05	1.33	0.20	0.96	2.19
PS 36:2; [M-H]-@5.95	ME191160	0.18	1.09	1.42	0.25	0.98	2.07
PE 35:4; [M-H]-@6.07	ME191083	0.20	1.02	1.21	0.36	1.05	2.18
PG 34:3; [M-H]-@4.67	ME191120	0.22	1.13	1.06	0.32	1.01	2.26
PS 36:3; [M-H]-@5.68	ME191161	0.33	0.80	1.45	0.24	1.02	2.17
plasmenyl-PE 38:3; [M-H]-@7.66	ME191183	0.24	0.73	1.74	0.30	0.96	2.02
plasmenyl-PE 40:3; [M-H]-@8.18	ME191187	0.25	0.79	1.61	0.24	1.00	2.11
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.91	ME191019	0.40	1.01	1.48	0.27	0.67	2.05
PG 32:1; [M-H]-@5.24	ME191114	0.36	1.12	1.62	0.28	0.73	1.80
PG 36:5; [M-H]-@4.74	ME191126	0.10	0.70	1.40	0.27	1.65	2.09
PE 39:2; [M-H]-@7.75	ME191098	0.26	1.07	0.82	0.62	1.34	2.00
PE 42:4; [M-H]-@8.04	ME191108	0.19	0.89	1.22	0.29	1.38	2.17
PS 37:3; [M-H]-@6.10	ME191163	0.24	0.74	1.15	0.36	1.31	2.30
CL 76:5; [M-2H](2-)@6.97	ME190992	0.31	0.84	0.89	0.55	1.23	2.26
PE 39:3; [M-H]-@7.58	ME191099	0.22	0.85	1.06	0.52	1.39	2.10
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.43	ME191018	0.83	0.63	1.68	0.83	0.59	1.31
PC 38:5; [M-Ac-H]-@6.56	ME191059	0.87	0.68	1.74	0.88	0.86	0.92
PC 42:10; [M-Ac-H]-@5.74	ME191066	0.85	0.64	1.75	0.72	0.91	1.10
PI 40:6; [M-H]-@5.82	ME191156	0.69	0.63	1.88	0.82	0.90	1.04
PI 38:4; [M-H]-@5.79	ME191152	0.64	0.71	1.93	1.09	0.83	0.74
PI 40:5; [M-H]-@5.99	ME191155	0.66	0.55	2.11	0.85	0.83	0.94
CL 72:6; [M-2H](2-)@9.31	ME190989	0.79	0.43	1.70	0.79	1.22	1.14
PA 36:4; [M-H]-@6.19	ME191027	0.54	0.77	1.79	0.69	1.26	1.02
PI 38:2; [M-H]-@6.52	ME191150	0.55	0.61	1.70	0.66	1.33	1.26
PI 38:3; [M-H]-@6.20	ME191151	0.53	0.57	1.91	0.67	1.21	1.19
FFA(18:2)	ME191000	0.40	0.97	1.77	0.49	0.80	1.50
plasmenyl-PE 42:5; [M-H]-@8.01	ME191190	0.48	1.00	1.74	0.55	0.79	1.37
CL 68:4; [M-2H](2-)@9.20	ME190983	0.45	0.86	1.64	0.65	0.88	1.49
PC 36:0; [M-Ac-H]-@7.91	ME191049	0.52	0.85	1.76	0.56	0.81	1.43
PC 36:5; [M-Ac-H]-@5.78	ME191052	0.55	0.87	1.68	0.50	0.93	1.45
PI 36:4; [M-H]-@5.26	ME191149	0.37	0.80	1.85	0.75	0.67	1.46
FFA(20:0)	ME191001	0.48	0.79	1.89	0.72	0.83	1.23
plasmenyl-PE 40:4; [M-H]-@7.84	ME191188	0.38	0.77	1.85	0.70	0.92	1.36
FFA(16:0)	ME190997	0.57	1.04	1.67	0.62	0.90	1.16
PE 37:5; [M-H]-@6.22	ME191091	0.44	0.97	1.71	0.75	0.99	1.15
FFA(18:0)	ME190998	0.55	0.95	1.84	0.77	0.84	1.00
plasmenyl-PE 34:1; [M-H]-@7.21	ME191177	0.56	0.98	1.63	0.87	0.77	1.11
PC 38:7; [M-Ac-H]-@5.59	ME191061	0.45	0.82	1.59	0.88	1.03	1.24
CL 70:4; [M-2H](2-)@9.42	ME190985	0.48	0.82	1.60	0.94	1.04	1.13
N-(dodecanoyl)-sphing-4-enine; [M-H]-@5.51	ME191015	0.45	0.87	1.65	0.88	1.05	1.11
CL 70:5; [M-2H](2-)@9.28	ME190986	0.64	0.76	1.61	0.84	0.83	1.27
FFA(22:0)	ME191005	0.64	0.74	1.65	0.95	0.85	1.11
PG 33:1; [M-H]-@5.56	ME191117	0.22	0.88	2.04	0.42	0.87	1.52
CL 68:5; [M-2H](2-)@9.01	ME190984	0.37	0.49	2.24	0.62	1.00	1.29
PI 34:2; [M-H]-@5.25	ME191145	0.45	0.72	2.10	0.52	0.93	1.27
PI 36:3; [M-H]-@5.62	ME191148	0.34	0.67	1.99	0.57	0.91	1.50
plasmenyl-PE 36:3; [M-H]-@7.14	ME191180	0.36	0.62	2.08	0.58	0.95	1.41
CerP 42:2; [M-H]-@7.82	ME190996	0.55	0.86	2.07	0.61	0.92	0.96
plasmenyl-PE 42:6; [M-H]-@7.78	ME191191	0.33	0.90	2.05	0.65	0.86	1.17
PC 38:4; [M-Ac-H]-@6.78	ME191058	0.71	0.83	1.80	0.40	0.97	1.27
PC 34:2; [M-Ac-H]-@6.30	ME191045	0.40	0.97	1.88	0.53	1.14	1.12
PC 37:4; [M-Ac-H]-@6.57	ME191056	0.57	0.69	1.92	0.41	1.21	1.27
PG 34:1; [M-H]-@5.83	ME191118	0.49	0.79	1.97	0.50	1.15	1.16
CL 68:3; [M-2H](2-)@9.39	ME190982	0.27	0.72	1.80	0.46	1.49	1.41
PC 28:0; [M-Ac-H]-@5.34	ME191031	0.26	0.93	1.80	0.37	1.52	1.30
PS 34:2; [M-H]-@5.36	ME191159	0.21	1.09	1.78	0.27	1.24	1.48
PS 32:1; [M-H]-@5.22	ME191157	0.33	1.00	1.98	0.30	1.16	1.29
PS 40:6; [M-H]-@6.32	ME191170	0.29	0.99	1.85	0.41	1.16	1.34
CL 66:3; [M-2H](2-)@5.87	ME190979	0.29	1.45	1.50	0.18	1.44	1.28
PA 36:1; [M-H]-@6.41	ME191025	0.44	1.45	1.24	0.47	1.42	1.11
PS 38:6; [M-H]-@5.24	ME191167	0.51	1.52	1.39	0.34	1.25	1.08
PE 32:1; [M-H]-@6.26	ME191073	0.32	1.40	1.42	0.47	1.10	1.33
PE 35:2; [M-H]-@6.71	ME191081	0.30	1.29	1.31	0.58	1.08	1.48
PE 40:8; [M-H]-@6.07	ME191105	0.40	1.21	1.54	0.43	1.23	1.26
PA 32:1; [M-H]-@6.07	ME191021	0.48	1.32	1.42	0.44	1.14	1.26
PE 38:6; [M-H]-@6.13	ME191096	0.48	1.22	1.50	0.45	1.11	1.28
PG 36:2; [M-H]-@6.07	ME191123	0.41	1.24	1.51	0.65	0.93	1.24
N-(hexadecanoyl)-sphinganine; [M-H]-@7.07	ME191017	0.60	1.14	1.40	0.57	0.96	1.32
PC 34:1; [M-Ac-H]-@6.74	ME191044	0.51	1.11	1.41	0.57	1.10	1.33
PC 36:3; [M-Ac-H]-@6.56	ME191051	0.58	0.97	1.60	0.51	1.35	1.10
PC 30:0; [M-Ac-H]-@6.00	ME191033	0.40	0.96	1.65	0.50	1.08	1.43
CL 74:7; [M-2H](2-)@6.11	ME190991	0.48	1.06	1.56	0.54	1.14	1.26
PE 36:2; [M-H]-@6.30	ME191086	0.45	1.02	1.69	0.59	1.16	1.15
PG 32:2; [M-H]-@4.75	ME191115	0.24	1.12	1.52	0.49	1.02	1.60
PG 34:2; [M-H]-@5.23	ME191119	0.26	1.13	1.54	0.51	0.84	1.67
PE 30:0; [M-H]-@6.11	ME191069	0.25	1.51	1.33	0.41	0.89	1.57
CL 74:11; [M-2H](2-)@5.63	ME190990	0.45	1.44	1.39	0.26	0.95	1.49
PE 36:5; [M-H]-@5.91	ME191087	0.39	1.22	1.51	0.27	1.01	1.60
PE 36:6; [M-H]-@5.46	ME191088	0.41	1.34	1.40	0.15	1.05	1.66
N-(9Z-octadecenoyl)-sphing-4-enine; [M-H]-@6.99	ME191014	0.68	0.81	1.31	0.87	1.24	1.18
PE 40:2; [M-H]-@7.51	ME191101	0.65	0.72	1.35	0.93	1.27	1.16
PG 38:2; [M-H]-@6.21	ME191127	0.39	0.79	1.45	1.02	1.30	1.15
PI 36:1; [M-H]-@6.32	ME191146	0.39	0.77	1.39	1.10	1.37	1.11
CerP 34:1; [M-H]-@5.91	ME190995	0.50	0.77	1.54	1.08	1.18	0.98
PC 37:2; [M-Ac-H]-@7.24	ME191054	0.46	0.92	1.49	0.94	1.26	1.01
PC 38:2; [M-Ac-H]-@7.52	ME191057	0.55	0.76	1.48	0.76	1.50	1.12
PC 33:2; [M-Ac-H]-@6.06	ME191043	0.36	1.05	1.52	0.73	1.42	1.07
PC 33:1; [M-Ac-H]-@6.46	ME191042	0.25	0.94	1.55	0.84	1.34	1.21
PC 35:1; [M-Ac-H]-@7.09	ME191047	0.38	0.85	1.48	0.88	1.38	1.15
PG 40:6; [M-H]-@5.47	ME191134	0.41	0.93	1.33	0.88	1.39	1.19
PE 35:0; [M-H]-@7.54	ME191079	0.29	1.16	1.14	1.13	1.21	1.14
PE 35:1; [M-H]-@6.46	ME191080	0.29	1.12	1.20	0.81	1.32	1.36
PE 37:1; [M-H]-@7.61	ME191089	0.35	1.20	1.01	0.75	1.47	1.38
PC 31:0; [M-Ac-H]-@6.27	ME191036	0.36	1.12	1.24	0.76	1.53	1.16
PE 36:1; [M-H]-@7.47	ME191085	0.48	1.12	1.30	0.85	1.35	1.01
PS 42:5; [M-H]-@6.67	ME191171	0.39	1.12	1.12	0.24	1.71	1.66
PG 40:5; [M-H]-@5.86	ME191133	0.24	0.74	1.15	0.71	1.79	1.64
PS 40:4; [M-H]-@6.37	ME191168	0.25	0.81	1.17	0.47	1.69	1.84
PS 36:4; [M-H]-@5.36	ME191162	0.52	0.62	1.55	0.42	1.77	1.38
PA 34:2; [M-H]-@6.17	ME191023	0.50	0.72	1.43	0.58	1.75	1.27
PC 40:4; [M-Ac-H]-@7.34	ME191064	0.40	0.69	1.44	0.53	1.79	1.42
PC 37:1; [M-Ac-H]-@7.66	ME191053	0.33	1.06	1.19	0.64	1.82	1.23
PG 38:3; [M-H]-@5.83	ME191128	0.38	0.87	1.17	0.82	1.81	1.22
PE 33:1; [M-H]-@6.58	ME191075	0.20	0.94	1.51	0.67	1.61	1.27
PE 42:5; [M-H]-@7.63	ME191109	0.26	0.88	1.57	0.62	1.49	1.34
PC 31:1; [M-Ac-H]-@5.89	ME191037	0.23	0.86	1.56	0.71	1.83	1.09
PE 33:0; [M-H]-@6.29	ME191074	0.22	1.02	1.40	0.69	1.75	1.16
PC 30:2; [M-Ac-H]-@5.03	ME191035	0.28	0.97	1.41	0.33	1.45	1.70
PG 36:3; [M-H]-@5.35	ME191124	0.27	1.06	1.30	0.49	1.49	1.56
PG 38:4; [M-H]-@5.54	ME191129	0.24	0.92	1.34	0.61	1.60	1.48
PG 32:0; [M-H]-@5.78	ME191113	0.34	1.10	1.49	0.31	1.67	1.30
PC 30:1; [M-Ac-H]-@5.51	ME191034	0.38	1.22	1.42	0.45	1.57	1.15
PC 32:2; [M-Ac-H]-@5.70	ME191039	0.36	1.16	1.46	0.39	1.53	1.28
PE 39:1; [M-H]-@7.59	ME191097	0.42	1.09	1.47	0.45	1.31	1.36
CL 66:1; [M-2H](2-)@5.50	ME190978	0.35	1.05	1.54	0.36	1.41	1.44
PC 32:3; [M-Ac-H]-@5.36	ME191040	0.33	1.07	1.43	0.32	1.52	1.50
PS 38:5; [M-H]-@5.52	ME191166	0.56	0.86	1.57	0.38	1.44	1.34
PC 32:1; [M-Ac-H]-@6.18	ME191038	0.40	0.87	1.44	0.45	1.51	1.50
PC 34:3; [M-Ac-H]-@5.95	ME191046	0.42	0.90	1.48	0.40	1.62	1.38
PC 40:3; [M-Ac-H]-@7.71	ME191063	0.54	0.79	1.31	0.65	1.44	1.42
PE 38:0; [M-H]-@7.95	ME191092	0.73	0.86	1.18	0.65	1.49	1.25
PE 38:2; [M-H]-@7.56	ME191094	0.56	1.01	1.23	0.67	1.44	1.25
PC 36:1; [M-Ac-H]-@7.42	ME191050	0.83	0.82	1.27	0.52	1.23	1.41
CL 68:2; [M-2H](2-)@9.59	ME190981	0.69	0.82	1.46	0.35	1.24	1.51
PC 42:2; [M-Ac-H]-@8.58	ME191067	0.54	0.98	1.33	0.44	1.33	1.48
PG 44:12; [M-H]-@4.50	ME191143	0.50	0.58	1.60	1.41	0.67	1.12
PG 42:10; [M-H]-@4.64	ME191137	0.28	0.60	1.31	1.34	0.80	1.60
PG 44:10; [M-H]-@5.35	ME191141	0.31	0.51	1.66	1.01	0.74	1.69
PG 44:11; [M-H]-@4.90	ME191142	0.33	0.44	1.64	1.20	0.83	1.51
CerP 32:0; [M-H]-@5.43	ME190993	0.37	1.12	1.39	0.99	0.71	1.32
FFA(20:4) Arachidonic acid	ME191004	0.56	1.18	1.39	0.86	0.59	1.27
lysoPE 18:1; [M-H]-@1.81	ME191173	0.95	0.72	1.18	0.89	0.84	1.37
PA 32:0; [M-H]-@6.67	ME191020	0.84	0.93	1.09	1.15	0.84	1.09
PC 40:6; [M-Ac-H]-@6.71	ME191065	0.92	0.75	1.72	0.51	1.49	0.78
PE 38:1; [M-H]-@7.43	ME191093	1.04	0.92	1.09	0.54	1.41	1.14
PG 33:0; [M-H]-@6.08	ME191116	0.43	0.60	2.07	0.95	1.27	0.76
PI 36:2; [M-H]-@5.86	ME191147	0.38	0.63	1.93	1.13	1.12	0.84
CerP 34:0; [M-H]-@6.17	ME190994	0.65	0.67	1.61	1.25	1.37	0.58
PA 35:1; [M-H]-@6.83	ME191024	0.75	0.71	1.58	1.13	1.49	0.50
CL 72:5; [M-2H](2-)@9.51	ME190988	0.94	0.91	1.43	0.87	1.20	0.71
PA 34:1; [M-H]-@6.77	ME191022	0.69	0.84	1.40	0.95	1.52	0.78
PA 38:2; [M-H]-@7.54	ME191028	1.02	0.78	1.21	0.99	1.55	0.64
PC 29:0; [M-Ac-H]-@5.64	ME191032	0.48	1.13	1.77	0.79	1.27	0.65
PE 32:0; [M-H]-@6.77	ME191072	0.49	1.24	1.59	1.02	0.83	0.78
PE 41:6; [M-H]-@7.11	ME191106	0.58	1.34	1.23	0.97	0.99	0.88
FFA(18:1)	ME190999	0.59	1.08	1.34	1.02	0.95	1.01
PE 40:6; [M-H]-@6.78	ME191104	0.74	0.88	1.33	1.06	1.04	0.96
PC 35:2; [M-Ac-H]-@6.65	ME191048	0.44	1.02	1.53	1.06	1.17	0.83
PI 39:4; [M-H]-@6.19	ME191154	0.55	1.01	1.56	0.96	1.07	0.88
PA 36:2; [M-H]-@6.78	ME191026	0.69	0.92	1.48	1.07	1.20	0.71
PE 36:0; [M-H]-@7.35	ME191084	0.67	0.72	1.50	1.25	1.09	0.80
PE 42:7; [M-H]-@6.96	ME191110	0.56	0.82	1.47	1.18	1.22	0.82
PA 38:6; [M-H]-@6.21	ME191030	0.48	0.96	1.67	1.27	0.95	0.66
CL 72:4; [M-2H](2-)@9.67	ME190987	0.78	0.76	1.51	1.22	0.79	0.86
FFA(24:0)	ME191009	0.60	0.74	1.67	1.37	0.77	0.76

Factors:

F1	Construct:GCKR_52621
F2	Construct:GCKR(P446L)
F3	Construct:GCKR(WT)
F4	Construct:NT
F5	Construct:PPP1R3B
F6	Construct:Vector

Data matrix